Meet Ajit Bisen, M.D.
Ajit K. Bisen, M.D., MBA
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Affiliate Faculty, Clinical Cancer Genetics Program, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Affiliate Faculty, Clinical Cancer Genetics Program, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2018 | UT Dallas Jindal School of Management, Dallas, Texas, US, MBA, Healthcare Leadership and Management |
| 2009 | St. George’s University School of Medicine, St. George, GD, M.D |
| 2004 | University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US, B.S. Computer Science |
Postgraduate Training
| 2017-2020 | Clinical Fellowship, Hematology and Oncology, UT Southwestern Medical Center, Dallas, Texas |
| 2013-2014 | Clinical Fellowship, Hematology and Oncology, The Ohio State University, Columbus, Ohio |
| 2009-2012 | Clinical Residency, Internal Medicine, Penn State University Hershey Medical Center, Hershey, Pennsylvania |
Board Certifications
| 2020 | American Board of Medical Oncology |
| 2020 | American Board of Hematology |
| 2012 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Assistant Professor, The University of Texas Southwestern Medical Center, Dallas, Texas, 2014 - 2017
Assistant Professor, Parkland Hospital, Dallas, Texas, 2014 - 2015
Clinical Assistant Professor of Medicine, Penn State College of Medicine, Hershey, Pennsylvania, 2013 - 2013
Assistant Professor, Lebanon VA Medical Center, Lebanon, Pennsylvania, 2012 - 2013
Administrative Appointments/Responsibilities
Dept of General Oncology Faculty Lead at West Houston HAL, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present
Other Appointments/Responsibilities
President Elect, Texas Society of Clinical Oncology, Texas, 2024 - Present
Affiliate Faculty Collaborator and Student Mentor, Pre-Health Honors Research Course, Baylor University, Office of Pre-Health Studies, Baylor University, Waco, Texas, 2024 - Present
MD Anderson Cancer Center Community Relations Ambassador, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Medical Advisory Board Member, Indian American Cancer Network (iacannetwork.org), 2023 - Present
Assistant Professor, Oncology Hospitalist, UT Southwestern Medical Center, Dallas, Texas, 2015 - 2017
Institutional Committee Activities
Associate Quality Officer, Breast Medical Oncology Quality Committee, 2025 - Present
Tumor Board Co-Moderator, Department of Breast Medical Oncology Weekly Case Conference, 2024 - Present
Faculty Wellness Officer, Department of General Oncology, Wellness Working Group, Division of Cancer Medicine, 2024 - Present
Tumor Board Moderator, Breast Oncology Weekly Multidisciplinary Tumor Board, West Houston HAL, 2024 - Present
Patient Safety Officer, MD Anderson West Houston HAL Quality and Safety Committee, 2023 - Present
Member, MD Anderson IRB Committee, 2023 - 2024
Member, Internal Guideline Committee for Breast Lobular Carcinoma, Department of Breast Medical Oncology, 2022 - Present
Member, Multidisciplinary Breast Tumor Board planning committee, West Houston HAL, 2022 - Present
Member, Wellness Working Group, Department of Breast Medical Oncology, 2021 - Present
Honors & Awards
| 2024 | Ranked Top 1% Nationally, Consumer Assessment of Healthcare Providers and Systems (CAHPS), The University of Texas MD Anderson Cancer Center |
| 2022 | Highest Award for Achievement, Dale Carnegie Effective Communications and Human Relations Program |
| 2018 | Outstanding Fellow Recognition Award, Texas Society of Clinical Oncology |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Yam, C, Patel, MM, Hill, H, Sun, R, Bassett Jr, R, Kong, EK, Damodaran, S, Koenig, KB, Abouharb, S, Saleem, S, Bisen, AK, Murthy, RK, Ramirez, DL, Rauch, GM, Adrada, BE, Candelaria, RP, Wang, X, Mittendorf, EA, Thompson, A, White, JB, Ravenberg, EE, Clayborn, A, Ding, Q, Booser, DJ, Oke, OC, Brewster, A, Hortobagyi, GN, Ibrahim, NK, Litton, J, Valero, V, Arun, BK, Tripathy, D, Chang, J, Chen, K, Korkut, A, Moulder, S, Huo, L, Lim, B, Ueno, NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Research Communications 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
- Chamani, IJ, Gannon, A, Connell, PT, Bisen, AK, Kovanci, E, Sangi-Haghpeykar, H, Woodard, TL, McKenzie, LJ. Dose-Dense Chemotherapy Regimen for Breast Cancer Associated with Significant Decline in Ovarian Reserve. Journal of adolescent and young adult oncology 13(3):465-468, 2024. e-Pub 2024. PMID: 38112555.
- Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA. Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. Br J Cancer 119(8):928-936, 2018. e-Pub 2018. PMID: 30318513.
- Garcia S, Bisen A, Yan J, Xie XJ, Ramalingam S, Schiller JH, Johnson DH, Gerber DE. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol 12(10):1489-1495, 2017. e-Pub 2017. PMID: 28802905.
Other Articles
- Bisen A, Claxton DF Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms. Adv Exp Med Biol 779:179-96, 2013. PMID: 23288640.
Abstracts
- Bisen A. Abstract HER2-01: HER2-01 Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer. AACR, 2023. e-Pub 2023.
- Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser D, Tripathy D. Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer, 2022. e-Pub 2022.
- Leitzel K, Ali S, Bisen A, Lomakin A, Simonyan V, Lipton A. Multiplex plasma biomarkers associated with bone metastasis from breast cancer. American Association for Cancer Research 71(24), 2011. e-Pub 2011.
Selected Presentations & Talks
Local Presentations
- 2024. Multidisciplinary approaches to SLN and ALND omission based on the SOUND, SENOMAC, and AMAROS trials. Invited. Breast Cancer Clinical and Translational Research (BCCTR) Conference. Houston, Texas, US.
- 2024. Multidisciplinary Approach to Early-Stage Breast Cancer Management. Conference. Research Educational Series. Houston, TX, US.
- 2024. First Diagnosis of Metastatic Breast Cancer. Invited. BMO Research Educational Series. Houston, Texas, US.
- 2024. The Prevalence of and Progress in Breast Cancer Management. Invited. IACAN (Indian American Cancer Network) Annual Breast Health Awareness Program. Houston, Texas, US.
- 2024. Multidisciplinary Approach to Early-Stage Breast Cancer Management. Conference. Breast Medical Oncology Educational Meeting, US.
- 2024. Treatment Crossroads: What is your approach to treating patients after CDK 4/6 progression?. Invited. OncLive State of the Science Summit: Breast Cancer. Houston, Texas, US.
- 2024. Hormone Receptor Positive Metastatic Breast Cancer. Invited. Grand Round Presentation. Houston, Texas, US.
- 2024. Career Day Speaker. Invited. Houston, Texas, US.
- 2018. New Kids on the Block, SERD, PROTAC, and CERANs. Updates in Advanced Breast Cancer Conference. Invited. Houston, Texas, US.
Regional Presentations
- 2024. Physician Burnout and Wellness in the Healthcare Environment. Invited. TxSCO (Texas Society of Clinical Oncology) Annual Conference. San Antonio, Texas, US.
- 2023. Recent Advances and Updates in Breast Cancer Research and Treatment. Invited. Texas Society of Clinical Oncology Annual Conference, Texas, US.
- 2018. Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity. Poster. TxSCO (Texas Society of Clinical Oncology) Annual Conference. Houston, Texas, US.
National Presentations
- 2025. Hormone Receptor Positive, HER2 Negative Breast Cancer. Invited. Nevada Oncology Society Official Review of SABCS. Las Vegas, NV, US.
- 2011. Multiplex plasma biomarkers associated with bone metastasis from breast cancer. Conference. 34th San Antonio Breast Cancer Symposium. San Antonio, TX, US.
International Presentations
- 2017. Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity. Conference. IASLC - International Association for the Study of Lung Cancer. Santa Monica, US.
Formal Peers
- 2023. Updates in Management of Breast Cancer, Monthly Education Series, MD Anderson West Houston. Houston, Texas, US.
Patient Reviews
CV information above last modified April 02, 2025